|Full Name||SUMO1/sentrin specific peptidase 6|
|Product Description||Rabbit polyclonal antibody to SENP6 (SUMO1/sentrin specific peptidase 6)|
|Background||Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM]|
|Synonyms||FLJ11355 antibody, FLJ11887 antibody, KIAA0389 antibody, KIAA0797 antibody, SSP1 antibody, SUSP1 antibody, SENP6 antibody, SUMO1/sentrin specific protease 6 antibody, SUMO-1-specific protease 1 antibody, sentrin-specific protease 6 antibody, 2810017C20Rik antibody, sentrin/SUMO-specific protease SENP6 antibody, SUMO1/sentrin specific peptidase 6 antibody|
|Cellular Localization||Nucleus |
|Immunogen||Carrier-protein conjugated synthetic peptide encompassing a sequence within the N-terminus region of human SENP6. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Predict Reactivity Note||Human (100%)|